The 5 most frequently asked questions about factor Xa inhibitors

Author:

Wang Tzu-Fei1,Carrier Marc1

Affiliation:

1. Department of Medicine, University of Ottawa at The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, ON, Canada

Abstract

AbstractDirect oral anticoagulants (DOACs) are commonly used oral factor Xa inhibitors in recent years. However, in some special clinical situations, the appropriate use of these anticoagulants may be of concern. In this article, we address the 5 commonly asked questions regarding their use for the treatment of venous thromboembolism, including in the setting of obesity, renal impairment, gastrointestinal (GI) malignancy, catheter-related thrombosis, and drug-drug interactions. Data on the use of DOACs in the presence of significant obesity or renal failure are mainly observational. Some DOACs are shown to have an increased risk of bleeding in patients with unresected luminal GI malignancy but not others, so selection of appropriate patients is the key. Furthermore, literature on the use of DOACs for catheter-related thrombosis or when drug-drug interactions are of concern is limited, and more research is welcome.

Publisher

American Society of Hematology

Subject

Hematology

Reference63 articles.

1. WHO recognition of the global obesity epidemic;James;Int J Obes (Lond),2008

2. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African- Americans;Takahashi;Pharmacogenet Genomics,2006

3. Low-molecular-weight heparin prophylaxis dosing: is weight an issue?;Minze;J Pharm Technol,2016

4. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH;Martin;J Thromb Haemost,2016

5. Treatment of venous thromboembolism with rivaroxaban in relation to body weight: a sub-analysis of the EINSTEIN DVT/PE studies;Di Nisio;Thromb Haemost,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3